HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 12, December 2019 – Precision Medicine for Brain Tumours       » First Alzheimer's drug to be approved in 17 years holds promise for treatment       » Tencent make medical information readily available to the public       » United States FDA approves first China-made cancer drug       » Value-Based Healthcare: A Paradigm Shift for Better Patient Outcomes       » Precision Agriculture for Future Nutritional Needs      
EYE ON CHINA
Vaccine maker Changsheng fined 9.1 billion yuan in safety scandal
Families of victims who died from the rabies vaccine will be given 650,000 yuan

Changchun Changsheng Biotech Co in Jilin province was forced to pay about 9.1 billion yuan (USD1.3 billion) in penalties on 16 October after the drugmaker was involved in a human rabies vaccine safety scandal in July, the State Drug Administration said.

A compensation plan for victims was also unveiled. Families of those who died due to the problematic vaccine will receive an one-off compensation of 650,000 yuan for each victim, and victims who became severely disabled or paralysed will get 500,000 yuan. The compensation will be 200,000 yuan for those mildly disabled, according to the plan.

The company, based in Changchun, Jilin, is a major vaccine producer and has been entangled in controversy since 15 July, when the State Drug Administration announced it found the company to be engaged in falsifying production and inspection records in the making of rabies vaccines.

Changsheng's illegal activities included using expired vaccine raw materials, altering production dates, forging permits and destroying evidence during inspections, the statement said.

The State Drug Administration annulled the rabies vaccine approval document and certificates for related products from the company and imposed a fine of 12.03 million yuan.

The Jilin Food and Drug Administration revoked the company's pharmaceutical production license, confiscated illegally produced vaccines and total income of 1.89 billion yuan from defective vaccine sales, and imposed a fine of 7.21 billion yuan, which was three times the value of the drugs it illegally produced and sold.

The total amount fined or confiscated stood at 9.1 billion yuan.

Source: China Daily

Click here for the complete issue.

NEWS CRUNCH  
news Proteona awards grant to clinician-scientist for research in treatment selection of multiple myeloma
news Technology giant, Tencent Holdings Limited, promotes medical science and healthcare
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
December:
Precision Medicine for Brain Tumours
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy